MCID: HMN014
MIFTS: 50

Human Immunodeficiency Virus Infectious Disease malady

Categories: Infectious diseases, Immune diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

Aliases & Descriptions for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 14
Hiv Infections 69
Hiv Infection 14

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD10 33 B20 B20-B20
ICD9CM 35 042 042-042.99
MeSH 42 D015658
NCIt 47 C3108
UMLS 69 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results_in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted_by sexual contact, transmitted_by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted_by congenital method, and transmitted_by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to hepatitis and tuberculosis, and has symptoms including diarrhea, fatigue and fever. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Emtricitabine and Lopinavir have been mentioned in the context of this disorder. Affiliated tissues include t cells and breast, and related phenotypes are cellular and hematopoietic system

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
id Related Disease Score Top Affiliating Genes
1 hepatitis 31.2 IFNG IL2 TNF
2 tuberculosis 31.1 CD4 IL2 TNF
3 pulmonary tuberculosis 30.5 CCL3 CCL5 IFNG TNF
4 susceptibility/resistance to hiv infection 12.0
5 hiv-1 11.8
6 syphilis 11.1
7 porphyria cutanea tarda 11.0
8 plasmablastic lymphoma 11.0
9 primary central nervous system lymphoma 11.0
10 mycobacterium avium complex disease 11.0
11 papular mucinosis 11.0
12 burkitt lymphoma 11.0
13 acquired immunodeficiency syndrome 11.0
14 immunodeficiency 13 10.8
15 pulmonary hypertension, familial primary, 1, with or without hht 10.7
16 cervical cancer, somatic 10.7
17 lung cancer susceptibility 3 10.7
18 efavirenz, poor metabolism of 10.7
19 tabes dorsalis 10.7
20 anus cancer 10.7
21 west nile fever 10.7
22 iga glomerulonephritis 10.7
23 idiopathic cd4-positive t-lymphocytopenia 10.7
24 linear lichen planus 10.7
25 stenotrophomonas maltophilia infection 10.7
26 aids - neurological complications 10.7
27 progressive locomotor ataxia 10.7
28 syphilitic spinal sclerosis 10.7
29 deep dermatophytosis 10.7
30 steatitis 10.4 IL2 TNF
31 autosomal dominant deafness-onychodystrophy syndrome 10.4 IFNG IL2 TNF
32 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.4 IFNG IL2 TNF
33 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.4 CCR5 IFNG TNF
34 46 xy gonadal dysgenesis 10.4 B2M CD4 CD79A
35 amyotrophic lateral sclerosis type 14 10.4 IFNG IL2 TNF
36 parametritis 10.4 IFNG IL2 TNF
37 cyclosporiasis 10.4 IFNG IL2 TNF
38 hemangioma of orbit 10.4 CD79A IL2 TNF
39 non-gestational choriocarcinoma 10.4 CCL5 CXCR4 IFNG
40 glucose intolerance 10.4 B2M IFNG TNF
41 ciliary discoordination, due to random ciliary orientation 10.4 CD4 CD79A IFNG
42 acute myeloid leukemia with recurrent genetic anomaly 10.4 IFNG IL2 TNF
43 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.4 CCL5 TNF
44 apricot allergy 10.4 CCL5 CD4 CD79A
45 hereditary alpha tryptasemia syndrome 10.4 B2M IFNG TNF
46 microcephaly 10.4 IFNG IL2 TNF
47 pulpitis 10.4 CCL5 IFNG TNF
48 rhabdomyosarcoma 10.4 CXCL12 CXCR4 IL2
49 uveitis 10.4 CD4 CD79A TNF
50 abnormal retinal correspondence 10.4 IFNG IL2 TNF

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

Symptoms:

12
  • diarrhea
  • fatigue
  • fever
  • vaginal yeast infection
  • headache
  • mouth sores
  • muscle aches
  • sore throat
  • swollen lymph gl

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 B2M CCR5 CD38 CD4 CD79A CXCL12
2 hematopoietic system MP:0005397 10.03 B2M CARTPT CCL5 CCR5 CD38 CD4
3 immune system MP:0005387 9.93 B2M CARTPT CCL5 CCR5 CD38 CD4
4 digestive/alimentary MP:0005381 9.92 ACTG1 B2M CCR5 CD4 CXCR4 IFNG
5 liver/biliary system MP:0005370 9.56 CXCL12 IFNG IL2 ITIH4 TNF B2M
6 neoplasm MP:0002006 9.23 ITIH4 TNF B2M CCR5 CD79A CXCR4

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 966)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 143491-57-0 60877
2
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 192725-17-0 92727
3
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 155213-67-5 392622
4
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147127-20-6 464205
5
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136470-78-5 65140 441300
6
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 134678-17-4 60825
7
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 52485-79-7 40400 644073
8
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
9
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 1 6493-05-6 4740
10
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
11
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
12
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1 1004316-88-4
13
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1 635728-49-3, 206361-99-1 213039
14
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1 500287-72-9
15
Rifabutin Approved Phase 4,Phase 2,Phase 3,Phase 1 72559-06-9 6323490
16
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1 723-46-6 5329
17
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 738-70-5 5578
18
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
19
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 154598-52-4 64139
20
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 159989-64-7 64143
21
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 30516-87-1 35370
22
Amprenavir Approved Phase 4,Phase 2,Phase 3,Phase 1 161814-49-9 65016
23
Artemether Approved Phase 4,Phase 3,Phase 1 71963-77-4 119380 68911
24
Lumefantrine Approved Phase 4,Phase 3,Phase 1 82186-77-4 6437380
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 129618-40-2 4463
27
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
28
Candesartan Approved Phase 4 139481-59-7 2541
29
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
30
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
32
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
33
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
34
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
35
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
36
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
37
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 376348-65-1 3002977
38
Ezetimibe Approved Phase 4,Phase 1 163222-33-1 150311
39
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
40
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 81093-37-0 54687
41
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
42
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1 74-55-5 3279 14052
43
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
44
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
45
Valganciclovir Approved, Investigational Phase 4,Phase 3 175865-60-8 64147
46
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
47
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159519-65-0 16130199
48
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
49
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
50
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 226700-79-4 131536

Interventional clinical trials:

(show top 50) (show all 5822)
id Name Status NCT ID Phase
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4
3 Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4
4 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4
7 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
8 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4
9 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
10 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4
11 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
12 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4
13 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4
14 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4
15 Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4
16 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Unknown status NCT01049685 Phase 4
17 Early Antiviral Therapy for Critically Ill HIV Infected Patients Unknown status NCT01455688 Phase 4
18 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4
19 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4
20 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4
21 BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects Unknown status NCT00388492 Phase 4
22 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4
23 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4
24 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4
25 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4
26 PrEP Demonstration Project (PRELUDE Study) Unknown status NCT02206555 Phase 4
27 The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling Unknown status NCT01843478 Phase 4
28 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4
29 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4
30 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4
31 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4
32 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
33 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
34 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4
35 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4
36 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4
37 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4
38 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4
39 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4
40 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism Unknown status NCT00759070 Phase 4
41 Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Unknown status NCT00751153 Phase 4
42 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Unknown status NCT01928407 Phase 4
43 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4
44 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4
45 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4
46 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
47 Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children Unknown status NCT00604617 Phase 4
48 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
49 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4
50 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

39
T Cells, Breast

Publications for Human Immunodeficiency Virus Infectious Disease

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 46)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 ACTG1 B2M CCL3 CCL4 CCL5 CCR5
2
Show member pathways
13.87 ACTG1 CCL3 CCL4 CCL5 CCR5 CD4
3
Show member pathways
13.65 CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
4
Show member pathways
13.55 CCL3 CCL4 CCL5 CD4 CXCL12 CXCR4
5
Show member pathways
13.41 ACTG1 CCL3 CCL4 CCL5 CCR5 CD4
6
Show member pathways
13.36 B2M CCL3 CCL4 CCL5 CCR5 CD4
7
Show member pathways
13.27 ACTG1 CCL3 CCL4 CCL5 CCR5 CD4
8
Show member pathways
12.93 CCL3 CCL4 CCL5 IFNA1 IFNG IL2
9
Show member pathways
12.89 ACTG1 CCL5 CCR5 CD4 CXCR4 TNF
10
Show member pathways
12.89 CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
11
Show member pathways
12.82 ACTG1 CCL5 IFNA1 IFNG IL2 TNF
12
Show member pathways
12.74 CCL4 CCL5 CXCL12 IFNA1 IFNG S100B
13
Show member pathways
12.67 CCR5 CD4 CXCR4 IFNG TNF
14
Show member pathways
12.64 CD4 CD79A IFNG IL2 TNF
15
Show member pathways
12.55 ACTG1 B2M CD4 CXCL12 CXCR4 IFNA1
16
Show member pathways
12.54 ACTG1 IFNA1 IFNG IL2 TNF
17
Show member pathways
12.45 CCR5 CD4 IFNG IL2 TNF
18
Show member pathways
12.32 CCL5 IFNG IL2 TNF
19
Show member pathways
12.17 IFNA1 IFNG IL2 TNF
20
Show member pathways
11.97 CCL3 CCL4 CCL5 CCR5 CXCL12 CXCR4
21
Show member pathways
11.96 CD4 IFNG IL2 TNF
22 11.88 CCL3 CCL5 CXCL12 IFNG TNF
23 11.87 CD38 CD4 CD79A IFNG IL2 TNF
24 11.85 ACTG1 CCL3 CCL4 IFNG
25 11.82 B2M CCL5 CD38 CD79A CXCL12 CXCR4
26 11.78 CCL3 CD4 IFNG IL2 TNF
27
Show member pathways
11.75 IFNG IL2 TNF
28 11.75 CD4 CXCL12 CXCR4
29 11.74 CD38 CD4 IFNG IL2 TNF
30 11.69 CCL3 CCL4 CCL5 TNF
31
Show member pathways
11.67 B2M IFNG IL2 TNF
32
Show member pathways
11.66 IFNG IL2 TNF
33 11.66 CXCL12 CXCR4 IFNA1 IFNG IL2
34 11.58 CD38 CD4 CXCR4
35 11.56 IFNG IL2 TNF
36
Show member pathways
11.55 B2M CCL3 CCL4 CCR5 CD4 IFNG
37 11.53 IFNG IL2 TNF
38 11.52 ACTG1 IFNG TNF
39 11.51 CD4 IFNG IL2
40 11.46 CCL3 CCL4 CCL5 CCR5 TNF
41 11.31 CCL5 CXCL12 CXCR4
42 11.31 CD4 IFNG IL2 TNF
43
Show member pathways
11.26 CCL3 CCL4 IFNG IL2 TNF
44 11.25 CD4 IFNG IL2
45 11.2 CCL3 CCL4 CCL5 CXCL12 IL2 TNF
46 10.64 CXCL12 TNF

GO Terms for Human Immunodeficiency Virus Infectious Disease

Cellular components related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 B2M CARTPT CCL3 CCL4 CCL5 CXCL12
2 cell surface GO:0009986 9.73 B2M CCR5 CD38 CD4 CXCR4 TNF
3 external side of plasma membrane GO:0009897 9.5 B2M CCR5 CD4 CD79A CXCL12 IFNG
4 extracellular space GO:0005615 9.4 ACTG1 B2M CARTPT CCL3 CCL4 CCL5

Biological processes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.96 CD4 CD79A IFNA1 IFNG IL2
2 positive regulation of protein phosphorylation GO:0001934 9.95 CD4 IFNG IL2 TNF
3 cell-cell signaling GO:0007267 9.95 CARTPT CCL3 CCL4 CCL5 CCR5 IL2
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.94 CCR5 CD38 CXCR4 IL2
5 cellular response to lipopolysaccharide GO:0071222 9.93 B2M CCR5 IFNG TNF
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 CCL3 CCL4 CCL5 CD4 TNF
7 movement of cell or subcellular component GO:0006928 9.88 ACTG1 CCL4 IFNG
8 cellular response to interleukin-1 GO:0071347 9.88 CCL3 CCL4 CCL5
9 cellular response to organic cyclic compound GO:0071407 9.87 CCL3 CCL5 TNF
10 cell chemotaxis GO:0060326 9.85 CCL3 CCL5 CXCL12
11 response to cytokine GO:0034097 9.85 CCL5 CD38 ITIH4
12 cellular response to interferon-gamma GO:0071346 9.85 CCL3 CCL4 CCL5
13 humoral immune response GO:0006959 9.84 IFNA1 IFNG TNF
14 calcium-mediated signaling GO:0019722 9.83 CCL3 CCR5 CXCR4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 CCL5 IFNG IL2
16 regulation of insulin secretion GO:0050796 9.83 CARTPT CCL5 IFNG TNF
17 negative regulation of viral genome replication GO:0045071 9.82 APOBEC3G CCL5 TNF
18 monocyte chemotaxis GO:0002548 9.82 CCL3 CCL4 CCL5
19 positive chemotaxis GO:0050918 9.81 CCL3 CCL5 CXCL12
20 neutrophil chemotaxis GO:0030593 9.81 CCL3 CCL4 CCL5 IFNG
21 protein kinase B signaling GO:0043491 9.8 CCL3 CCL5 TNF
22 positive regulation of T cell proliferation GO:0042102 9.8 CCL5 CD4 IFNG IL2
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 CCL3 CCL5 TNF
24 positive regulation of calcium ion transport GO:0051928 9.77 CCL3 CCL4 CCL5
25 positive regulation of calcium-mediated signaling GO:0050850 9.74 CCL3 CCL4 CD4
26 positive regulation of cell adhesion GO:0045785 9.73 CCL5 CXCL12 IFNG TNF
27 chemotaxis GO:0006935 9.73 CCL3 CCL4 CCL5 CCR5 CXCL12 CXCR4
28 dendritic cell chemotaxis GO:0002407 9.72 CCL5 CCR5 CXCR4
29 macrophage chemotaxis GO:0048246 9.71 CCL3 CCL5
30 positive regulation of T cell migration GO:2000406 9.71 CCL5 CXCL12
31 negative regulation of bone resorption GO:0045779 9.71 CARTPT CD38
32 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IFNG TNF
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IFNG IL2
34 regulation of T cell activation GO:0050863 9.69 CCL5 CD4
35 response to cholesterol GO:0070723 9.68 CCL3 CCR5
36 signaling GO:0023052 9.68 CCL3 CCR5
37 eosinophil chemotaxis GO:0048245 9.68 CCL3 CCL5
38 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.67 CCL3 CCR5
39 negative regulation by host of viral transcription GO:0043922 9.63 CCL3 CCL4 CCL5
40 response to virus GO:0009615 9.63 CCL4 CCL5 CXCL12 CXCR4 IFNG TNF
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 IFNG TNF
42 positive regulation of vitamin D biosynthetic process GO:0060557 9.6 IFNG TNF
43 fusion of virus membrane with host plasma membrane GO:0019064 9.58 CCR5 CD4 CXCR4
44 positive regulation of natural killer cell chemotaxis GO:2000503 9.54 CCL3 CCL4 CCL5
45 entry into host cell GO:0030260 9.5 CCR5 CD4 CXCR4
46 chemokine-mediated signaling pathway GO:0070098 9.43 CCL3 CCL4 CCL5 CCR5 CXCL12 CXCR4
47 immune response GO:0006955 9.32 B2M CCL3 CCL4 CCL5 CCR5 CD4
48 G-protein coupled receptor signaling pathway GO:0007186 10.19 CARTPT CCL3 CCL4 CCL5 CCR5 CXCL12
49 immune system process GO:0002376 10.09 APOBEC3G B2M CD4 CD79A IL2
50 inflammatory response GO:0006954 10.05 CCL3 CCL4 CCL5 CCR5 CXCR4 TNF

Molecular functions related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.97 ACTG1 B2M CCL3 CCL4 S100B TNF
2 virus receptor activity GO:0001618 9.65 CCR5 CD4 CXCR4
3 chemokine activity GO:0008009 9.56 CCL3 CCL4 CCL5 CXCL12
4 coreceptor activity GO:0015026 9.54 CCR5 CD4 CXCR4
5 chemoattractant activity GO:0042056 9.5 CCL3 CCL5 CXCL12
6 chemokine receptor binding GO:0042379 9.46 CCL5 CXCL12
7 C-C chemokine binding GO:0019957 9.43 CCR5 CXCR4
8 phospholipase activator activity GO:0016004 9.4 CCL3 CCL5
9 CCR5 chemokine receptor binding GO:0031730 9.33 CCL3 CCL4 CCL5
10 cytokine activity GO:0005125 9.23 CCL3 CCL4